Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Medicinova Inc
(NQ:
MNOV
)
1.140
+0.010 (+0.88%)
Streaming Delayed Price
Updated: 2:48 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Medicinova Inc
< Previous
1
2
3
4
Next >
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
June 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
June 05, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
June 03, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
May 28, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
May 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
May 14, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024
May 10, 2024
MNOV stock results show that MediciNova missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
May 07, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
April 05, 2024
Via
Benzinga
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
April 02, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 27, 2024
Via
Benzinga
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
March 27, 2024
Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is possibly considering an offer for the company.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 27, 2024
It's time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news!
Via
InvestorPlace
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
March 26, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
March 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
March 12, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 13, 2024
Via
Benzinga
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
January 17, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
December 21, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
December 06, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Why Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?
November 20, 2023
MediciNova Inc's (NASDAQ: MNOV) collaborators presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the Annual Meeting of the
Via
Benzinga
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 20, 2023
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates...
Via
Benzinga
Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket
November 20, 2023
Shares of Applied UV, Inc. (NASDAQ: AUVI) shares jumped in pre-market trading after the company reported third-quarter results.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 20, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
November 20, 2023
It's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning!
Via
InvestorPlace
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
November 19, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
October 27, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
October 10, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.